Inhaled Extra-fine Hydrofluoalkane-beclomethasone (QVAR) in Premature Infants With Bronchopulmonary Dysplasia (BPD)

PHASE2UnknownINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
Bronchopulmonary Dysplasia
Interventions
DRUG

Inhaled extra-fine hydrofluoalkane-beclomethasone (QVAR)

Infants will be randomized for Inhaled QVAR 100 microgram or placebo twice daily with spontaneous tidal breathing for 30 seconds via aerochamber with face mask for the study period.

Trial Locations (1)

31048

RECRUITING

Bnai Zion Medical Center, Haifa

All Listed Sponsors
collaborator

Tel-Aviv Sourasky Medical Center

OTHER_GOV

collaborator

Schneider Children's Medical Center, Israel

OTHER

collaborator

Meir Hospital, Kfar Saba, Israel

OTHER

collaborator

Kaplan Medical Center

OTHER

collaborator

Barzilai Medical Center

OTHER

collaborator

Laniado Hospital

OTHER

collaborator

HaEmek Medical Center, Israel

OTHER

lead

Bnai Zion Medical Center

OTHER_GOV